Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease and inflammation diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional. Alexion Pharmaceuticals Inc. has a market cap of $3.83 billion; its shares were traded at around $43.54 with a P/E ratio of 51.2 and P/S ratio of 14.8.
Insiders' Positions with ALXN
- Sell:: CEO Leonard Bell sold 18,905 shares of ALXN stock on 10/12/2009 at the average price of 44.91, the price of the stock has decreased by 3.05% since
- Sell:: CEO Leonard Bell sold 20,000 shares of ALXN stock on 10/01/2009 at the average price of 43.76, the price of the stock has decreased by 0.5% since
- Sell:: CEO Leonard Bell sold 37,810 shares of ALXN stock on 09/01/2009 at the average price of 45.82, the price of the stock has decreased by 4.98% since
- Sell:: CEO Leonard Bell sold 1,251 shares of ALXN stock on 07/16/2009 at the average price of 38.96, the price of the stock has increased by 11.76% since
- Sell:: CEO Leonard Bell sold 1,173 shares of ALXN stock on 07/10/2009 at the average price of 36.93, the price of the stock has increased by 17.9% since
Insiders' Positions with ALXN
- Sell:: SVP & CFO Vikas Sinha sold 1,833 shares of ALXN stock on 09/22/2009 at the average price of 46.27, the price of the stock has decreased by 5.9% since
- Sell:: SVP & CFO Vikas Sinha sold 397 shares of ALXN stock on 07/16/2009 at the average price of 38.96, the price of the stock has increased by 11.76% since
- Sell:: SVP & CFO Vikas Sinha sold 318 shares of ALXN stock on 07/10/2009 at the average price of 36.93, the price of the stock has increased by 17.9% since
Insiders' Positions with ALXN
- Sell:: Director Larry Mathis sold 13,000 shares of ALXN stock on 10/27/2009 at the average price of 48.42, the price of the stock has decreased by 10.08% since
- Sell:: EVP & Head of Research Stephen P Squinto sold 45,800 shares of ALXN stock on 08/24/2009 at the average price of 45, the price of the stock has decreased by 3.24% since
- Sell:: Director R Douglas Norby sold 17,000 shares of ALXN stock on 08/24/2009 at the average price of 45, the price of the stock has decreased by 3.24% since
- Sell:: EVP & Head of Research Stephen P Squinto sold 4,200 shares of ALXN stock on 08/04/2009 at the average price of 45, the price of the stock has decreased by 3.24% since
- Sell:: Director R Douglas Norby sold 2,000 shares of ALXN stock on 08/04/2009 at the average price of 45, the price of the stock has decreased by 3.24% since
Become a Premium Member to See This: (Free Trial):
- CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
- Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
- Double Buys:: Companies that both Gurus and Insiders are buying
- Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.
Rate This Article: |
  |